As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Isatuximab in combination for untreated multiple myeloma when stem cell transplant is unsuitable.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during mid-April 2023.